Patty Delaney

Global Head of Project Management at Azura Ophthalmics

Patty joined Azura in June of 2018 as the Data Review Committee Chairperson and then transitioned to Head of Global Project Management in 2020. She has more than 23 years of experience in Portfolio and Project Management, as well as Finance, at two major pharmaceutical companies covering 11 therapeutic areas and managing a portfolio value over $500 million. Prior to Azura, Patty was a Sr. Portfolio Director for Allergan managing staff and performing portfolio and project management for Ophthalmics, Biologics and Dermatology from Discovery through NDA approvals. Prior to Allergan, she worked at Pfizer increasing in responsibilities from clinical finance, developing financial & portfolio modeling to assisting in drafting clinical strategies and managing a portfolio of over 50 projects for 11 different therapy areas, including ophthalmology. During her 13.5 years at Pfizer, she also led the design representing the occupants of a million square foot clinical building in New London, CT – winning the highest award offered to Clinical Research staff for exemplary customer focus in gathering, coordinating, and communicating the needs of the Clinical Research employees and translating it into the design of the new Global Development Research Facility. Her experience also included pre and post-merger and acquisitions business portfolio integration. Prior to Pfizer, she was an underwriter for Cigna and developed budgeting models for Mariner Health. She holds an BSBA in Finance from the University of Connecticut, and PMP certified 2010.

Location

Portland, United States

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Azura Ophthalmics

1 followers

Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the United States. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking.


Industries

Employees

11-50

Links